Novel methods development in health economic modeling

Relevant publications

1. O. Alagoz, S. Srinivasan, H. Xiao, P. Singh, J. Gricar, M. Dixon, I. Kim, and M. Kurt (2024). "A Generalized Framework for Eliciting Unreported Subgroup-Specific Events and Survival Outcomes from Aggregate Level Data: Analyses & Insights from Adjuvant & Advanced Stage Gastrointestinal Cancers." Poster presentation at ISPOR Annual Conference, May 5-8, 2024, Atlanta,Georgia. 

2. V. Vahdat, O. Alagoz, J.V. Chen, L. Saoud, B.J. Borah, P.J. Limburg (2023), “Calibration and Validation of Colorectal Cancer and Adenoma Incidence & Mortality (CRC-AIM) Microsimulation Model using Deep Neural Networks,” Medical Decision Making, 43(6):719-736.

3. O. Alagoz, S. Srinivasan, M. Dyer, J. May, A. Moshyk, and M. Kurt (2023). "Investigating recurrence-free survival (RFS)-overall survival (OS) correlation in Stage 2 melanoma via reconstructed survival data". Poster presentation at SMDM North American Annual Meeting,  October 22-25, 2023, Philadelphia, Pennsylvania.

4. O. Alagoz, J. Ajani, S. Srinivasan, I. Kim, P. Singh, and M. Kurt (2023). An indirect assessment of individual-level association between disease-free survival (DFS) and overall survival (OS) for resectable esophageal or gastroesophageal junction cancer (EC/GEJC): A pooled analysis of randomized controlled trials (RCTs) by an illness-death model.  Journal of Clinical Oncology, 41(4):S369. Poster presentation at ASCO Gastrointestinal Cancers Symposium, January 19-21, 2023, San Francisco, California.   

5. O. Alagoz, S. Srinivasan, I. Kim, and M. Kurt (2022). "MSR38 Can Logistic Regression (LOR) Better Predict the Significance of the Overall Survival (OS) from Surrogate Endpoints (SES) for Randomized Controlled Trials (RCTS) in Oncology? Insights From a Cross-Tumor Case Study." Value in Health 25(12): S357.  Poster presentation at ISPOR-Europe Annual Conference, November 6-9, 2022, Vienna, Austria, and virtual. 

6. O. Alagoz,  J. Ajani, S. Srinivasan, I. Kim, P. Singh, H. Xiao, and M. Kurt (2022). "Estimating endpoint correlation between surrogate measures and overall survival using reconstructed survival data: Case studies from adjuvant and metastatic gastric cancer trials." Annals of Oncology, 33: S267. Poster presentation at ESMO World Congress on Gastrointestinal Cancer,  June 29-July 2, 2022, Barcelona, Spain.

7. O. Alagoz, H. Xiao, P. Singh, J. Gricar, M. Dixon, I. Kim, and M. Kurt (2022). "P46 Effective Use of Reconstructed Survival and Comparative Effectiveness Data: A Case Study from Estimating Unreported Subgroup Survival in Advanced Stage Gastrointestinal Cancers." Value in Health 25(1): S10. Oral presentation at ISPOR-Europe Annual Conference, November 30-December 3, 2021, virtual.

8. O. Alagoz, S. Srinivasan, H. Xiao, P. Singh, J. Gricar, M. Dixon, I. Kim, and M. Kurt (2022). "MSR104 Assessing the Impact of Integrating Extrapolated Long-Term Outcomes Into Elicitation of Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTS): Insights From Advanced Stage Gastrointestinal Cancers." Value in Health 25(12): S370.  Poster presentation at ISPOR-Europe Annual Conference, November 6-9, 2022, Vienna, Austria, and virtual. 

9. O. Alagoz, S. Srinivasan, H. Xiao, P. Singh, J. Gricar, M. Dixon, I. Kim, and M. Kurt (2022). "MSR12 Eliciting Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTs): A Non-Parametric Linear Optimization Approach." Value in Health 25 (7): S519-S520. Poster presentation at ISPOR Annual Conference, May 15-18, 2022, Washington, DC. 

10. O. Alagoz, H. Xiao, P. Singh, J. Gricar, M. Dixon, and M. Kurt (2021). "CN2 Eliciting Unreported Subgroup-Specific Survival from Aggregate Randomized Controlled Trial Data." Value in Health 24 (2021): S3. Oral presentation at ISPOR Annual Conference, May 17-20, 2021, virtual.